

**FIRST CLASS MAIL CERTIFICATE**

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, United States Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202.

*Minda O. Palladino*  
Minda O. Palladino

January 25, 2002  
Date

Att. Docket No. REG 203-A



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Stahl, et al.  
Serial No. : 09/313,942 Notice of Allowance: November 16, 2001  
Filed : May 19, 1999  
For: RECEPTOR BASED ANTAGONISTS AND METHODS OF MAKING AND USING

Date: January 25, 2002

Commissioner for Patents  
U.S. Patent and Trademark Office  
Box Sequence  
P.O. Box 2327  
Arlington, VA 22202

**Match and Return**

Dear Sir:

**TRANSMITTAL OF SEQUENCE LISTING**

The Issue Fee and Publication Fees are being paid concurrently by First Class Mail (a copy of which is enclosed herewith as Exhibit 1).

Applicants noted when checking the file that a Sequence Listing had not been submitted. To correct this oversight, Applicants submit herewith as Exhibit 2: Sequence Listings in paper and computer readable form pursuant to 37 C.F.R §1.821(c) and (e) respectively.

Applicants direct the subject Sequence Listings submitted herewith be added to the specification.

11/01

**OK to Enter**

#24  
rb  
05/13/02

B  
Box Seq


Att. Docket No.: REG 2009-A  
USSN 09/313,942  
Transmittal of Sequence Listing

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R §1.821(c) and (e) respectively, are the same. I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted herewith and referred to herein in accordance with 37 C.F.R. § 1.821(g), contain no new matter.

Applicants are submitting a §1.312 amendment concurrently by First Class Mail to amend the specification to include the sequence identifiers and to comply with the rules regarding drawings containing multiple views. Applicants enclose herewith as Exhibit 3 a copy of the §1.312 Amendment.

No fee is deemed necessary in connection with this submission. However, if any fee is deemed necessary, authorization is hereby given to charge the fee to Deposit Account No. 18-0650.

Respectfully submitted,



Linda O. Palladino  
Reg. No. 45,636  
Patent Agent for Applicants  
Gail M. Kempler  
Reg. No. 32,143  
Joseph M. Sorrentino  
Reg. No. 32,598  
Laura J. Fischer  
Reg. No. P-50,420  
Attorneys for Applicants  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400